{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:43:19Z","timestamp":1785354199990,"version":"3.55.0"},"reference-count":107,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FAPESP","award":["2021\/04778-2"],"award-info":[{"award-number":["2021\/04778-2"]}]},{"name":"FAPESP","award":["2021\/11205-09"],"award-info":[{"award-number":["2021\/11205-09"]}]},{"name":"FAPESP","award":["2020\/13347-2"],"award-info":[{"award-number":["2020\/13347-2"]}]},{"name":"FAPESP","award":["303206\/2019-5"],"award-info":[{"award-number":["303206\/2019-5"]}]},{"name":"CNPq","award":["2021\/04778-2"],"award-info":[{"award-number":["2021\/04778-2"]}]},{"name":"CNPq","award":["2021\/11205-09"],"award-info":[{"award-number":["2021\/11205-09"]}]},{"name":"CNPq","award":["2020\/13347-2"],"award-info":[{"award-number":["2020\/13347-2"]}]},{"name":"CNPq","award":["303206\/2019-5"],"award-info":[{"award-number":["303206\/2019-5"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Neglected diseases, primarily found in tropical regions of the world, present a significant challenge for impoverished populations. Currently, there are 20 diseases considered neglected, which greatly impact the health of affected populations and result in difficult-to-control social and economic consequences. Unfortunately, for the majority of these diseases, there are few or no drugs available for patient treatment, and the few drugs that do exist often lack adequate safety and efficacy. As a result, there is a pressing need to discover and design new drugs to address these neglected diseases. This requires the identification of different targets and interactions to be studied. In recent years, there has been a growing focus on studying enzyme covalent inhibitors as a potential treatment for neglected diseases. In this review, we will explore examples of how these inhibitors have been used to target Human African Trypanosomiasis, Chagas disease, and Malaria, highlighting some of the most promising results so far. Ultimately, this review aims to inspire medicinal chemists to pursue the development of new drug candidates for these neglected diseases, and to encourage greater investment in research in this area.<\/jats:p>","DOI":"10.3390\/ph16071028","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T21:20:14Z","timestamp":1689801614000},"page":"1028","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Covalent Inhibitors for Neglected Diseases: An Exploration of Novel Therapeutic Options"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-7593","authenticated-orcid":false,"given":"Erick Tavares Marcelino","family":"Alves","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, Butant\u00e3, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1455-4613","authenticated-orcid":false,"given":"Filipe Gomes","family":"Pernichelle","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, Butant\u00e3, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Adriano","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, Butant\u00e3, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glaucio Monteiro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, Butant\u00e3, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Igne","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, Butant\u00e3, S\u00e3o Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"ref_1","unstructured":"(2023, March 18). Neglected Tropical Diseases. Available online: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/neglected-tropical-diseases."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1021\/acsinfecdis.0c00684","article-title":"Targeted Covalent Inhibitors for the Treatment of Malaria?","volume":"6","author":"Kulkarni","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/acsmedchemlett.8b00592","article-title":"Covalent Inhibitors of Plasmodium falciparum Glyceraldehyde 3-Phosphate Dehydrogenase with Antimalarial Activity in Vitro","volume":"10","author":"Cullia","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kerr, I.D., Wu, P., Marion-Tsukamaki, R., Mackey, Z.B., and Brinen, L.S. (2010). Crystal Structures of TbCatB and Rhodesain, Potential Chemotherapeutic Targets and Major Cysteine Proteases of Trypanosoma brucei. Tschudi, C.; editor. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000701"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25697","DOI":"10.1074\/jbc.M109.014340","article-title":"Vinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug Design","volume":"284","author":"Kerr","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0006-291X(68)90326-4","article-title":"On the active site of proteases. III. Mapping the active site of papain; specific peptide inhibitors of papain","volume":"32","author":"Schechter","year":"1968","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10617","DOI":"10.1021\/acs.jmedchem.9b00908","article-title":"Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis","volume":"62","author":"Ettari","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/cmdc.202000360","article-title":"Peptidyl Vinyl Ketone Irreversible Inhibitors of Rhodesain: Modifications of the P2 Fragment","volume":"15","author":"Maiorana","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1021\/acsmedchemlett.2c00084","article-title":"Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain","volume":"13","author":"Previti","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Previti, S., Ettari, R., Di Chio, C., Ravichandran, R., Bogacz, M., Hellmich, U.A., Schirmeister, T., Cosconati, S., and Zappal\u00e0, M. (2022). Development of Reduced Peptide Bond Pseudopeptide Michael Acceptors for the Treatment of Human African Trypanosomiasis. Molecules, 27.","DOI":"10.3390\/molecules27123765"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cmdc.202000158","article-title":"Development of Novel Benzodiazepine-Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense","volume":"15","author":"Previti","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114328","DOI":"10.1016\/j.ejmech.2022.114328","article-title":"Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei rhodesiense","volume":"236","author":"Previti","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1002\/chem.201103322","article-title":"Design, Synthesis and Biological Evaluation of Potent Azadipeptide Nitrile Inhibitors and Activity-Based Probes as Promising Anti-Trypanosoma brucei Agents","volume":"18","author":"Yang","year":"2012","journal-title":"Chem. Eur. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1021\/acs.jmedchem.7b00405","article-title":"Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases [NTDs]","volume":"60","author":"Previti","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1021\/acsmedchemlett.9b00635","article-title":"Drug Synergism: Studies of Combination of RK-52 and Curcumin against Rhodesain of Trypanosoma brucei rhodesiense","volume":"11","author":"Ettari","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/cmdc.201300390","article-title":"Development of Rhodesain Inhibitors with a 3-Bromoisoxazoline Warhead","volume":"8","author":"Ettari","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/cmdc.201500204","article-title":"Dipeptidyl Enoates As Potent Rhodesain Inhibitors That Display a Dual Mode of Action","volume":"10","author":"Royo","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1016\/j.bmc.2018.07.015","article-title":"Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates","volume":"26","author":"Royo","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1016\/j.bmcl.2016.06.047","article-title":"Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents","volume":"26","author":"Ettari","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3109\/14756366.2015.1108972","article-title":"Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors","volume":"31","author":"Ettari","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bmcl.2016.11.036","article-title":"Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei","volume":"27","author":"Schirmeister","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12322","DOI":"10.1021\/acs.jmedchem.1c01002","article-title":"Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure\u2013Activity Relationship, Inhibition Mechanism, Metabolism, and In Vivo Studies","volume":"64","author":"Jung","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1021\/acs.jmedchem.9b02078","article-title":"Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity","volume":"63","author":"Chenna","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1016\/j.bmcl.2015.08.074","article-title":"Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain","volume":"25","author":"McShan","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1039\/c2ob00034b","article-title":"Tuning and predicting biological affinity: Aryl nitriles as cysteine protease inhibitors","volume":"10","author":"Ehmke","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/cmdc.201300112","article-title":"Optimization of Triazine Nitriles as Rhodesain Inhibitors: Structure-Activity Relationships, Bioisosteric Imidazopyridine Nitriles, and X-ray Crystal Structure Analysis with Human Cathepsin L.","volume":"8","author":"Ehmke","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1021\/acs.jmedchem.7b01869","article-title":"Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors","volume":"61","author":"Giroud","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1021\/acs.jmedchem.7b01870","article-title":"2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design","volume":"61","author":"Giroud","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cmdc.201300399","article-title":"Toward the Development of Dual-Targeted Glyceraldehyde-3-phosphate Dehydrogenase\/Trypanothione Reductase Inhibitors against Trypanosoma brucei and Trypanosoma cruzi","volume":"9","author":"Belluti","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.bmcl.2018.03.039","article-title":"Discovery of a quinoline-based phenyl sulfone derivative as an antitrypanosomal agent","volume":"28","author":"Zhang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.freeradbiomed.2016.02.028","article-title":"The role of glutathione reductase and related enzymes on cellular redox homoeostasis network","volume":"95","author":"Couto","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1073\/pnas.95.9.5311","article-title":"Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: Effect on parasite intracellular survival","volume":"95","author":"Tovar","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27456","DOI":"10.1074\/jbc.M113.495101","article-title":"Ebsulfur Is a Benzisothiazolone Cytocidal Inhibitor Targeting the Trypanothione Reductase of Trypanosoma brucei","volume":"288","author":"Lu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Koch, O., Cappel, D., Nocker, M., J\u00e4ger, T., Floh\u00e9, L., Sotriffer, C.A., and Selzer, P.M. (2013). Molecular Dynamics Reveal Binding Mode of Glutathionylspermidine by Trypanothione Synthetase. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056788"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2015.11.023","article-title":"Inhibitory effect of phenothiazine- and phenoxazine-derived chloroacetamides on Leishmania major growth and Trypanosoma brucei trypanothione reductase","volume":"108","author":"Marcu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1700373","DOI":"10.1002\/ardp.201700373","article-title":"Molecular insights into trypanothione reductase-inhibitor interaction: A structure-based review","volume":"351","author":"Tiwari","year":"2018","journal-title":"Arch. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/14756366.2022.2045590","article-title":"Drug-like molecules with anti-trypanothione synthetase activity identified by high throughput screening","volume":"37","author":"Franco","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1074\/jbc.M111.338285","article-title":"High Throughput Screening against the Peroxidase Cascade of African Trypanosomes Identifies Antiparasitic Compounds That Inactivate Tryparedoxin","volume":"287","author":"Fueller","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Steverding, D. (2019). On the Reversible and Irreversible Inhibition of Rhodesain by Curcumin. Molecules, 25.","DOI":"10.3390\/molecules25010143"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1365-2958.2010.07236.x","article-title":"Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in mice: Essentiality of pteridine reductase 1","volume":"77","author":"Sienkiewicz","year":"2010","journal-title":"Mol. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1021\/jm500483b","article-title":"Structure-Based Design and Synthesis of Antiparasitic Pyrrolopyrimidines Targeting Pteridine Reductase 1","volume":"57","author":"Khalaf","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41564-020-0745-6","article-title":"Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors","volume":"5","author":"Saldivia","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e00712","DOI":"10.7554\/eLife.00712","article-title":"Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei","volume":"2","author":"Nishino","year":"2013","journal-title":"eLife"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e20190105","DOI":"10.1590\/0001-3765201920190105","article-title":"The role of natural products in modern drug discovery","volume":"91","author":"Calixto","year":"2019","journal-title":"An. Acad. Bras. Ci\u00eanc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.3390\/md12052614","article-title":"Identification of Plakortide E from the Caribbean Sponge Plakortis halichondroides as a Trypanocidal Protease Inhibitor using Bioactivity-Guided Fractionation","volume":"12","author":"Oli","year":"2014","journal-title":"Mar. Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"127217","DOI":"10.1016\/j.bmcl.2020.127217","article-title":"Vinyl sulfone-based inhibitors of trypanosomal cysteine protease rhodesain with improved antitrypanosomal activities","volume":"30","author":"Zhang","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lenz, M., Krauth-Siegel, R.L., and Schmidt, T.J. (2019). Natural Sesquiterpene Lactones of the 4,15-iso-Atriplicolide Type are Inhibitors of Trypanothione Reductase. Molecules, 24.","DOI":"10.3390\/molecules24203737"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Doyle, P.S., Zhou, Y.M., Hsieh, I., Greenbaum, D.C., McKerrow, J.H., and Engel, J.C. (2011). The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002139"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4155\/fmc-2020-0057","article-title":"Synthesis, biochemical evaluation and molecular modeling studies of nonpeptidic nitrile-based fluorinated compounds","volume":"13","author":"Lameiro","year":"2021","journal-title":"Future Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7688","DOI":"10.1021\/jm050686b","article-title":"Interaction of Papain-like Cysteine Proteases with Dipeptide-Derived Nitriles","volume":"48","author":"Schilling","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Avelar, L.A.A., Camilo, C.D., de Albuquerque, S., Fernandes, W.B., Gon\u00e7alez, C., Kenny, P.W., Leit\u00e3o, A., McKerrow, J.H., Montanari, C.A., and Orozco, E.V.M. (2015). Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003916"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bioorg.2018.04.006","article-title":"Leveraging the cruzain S3 subsite to increase affinity for reversible covalent inhibitors","volume":"79","author":"Cianni","year":"2018","journal-title":"Bioorg. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"116211","DOI":"10.1016\/j.bmc.2021.116211","article-title":"Nitrile-based peptoids as cysteine protease inhibitors","volume":"41","author":"Alves","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"24317","DOI":"10.1039\/C8CP03320J","article-title":"Experimental study and computational modelling of cruzain cysteine protease inhibition by dipeptidyl nitriles","volume":"20","author":"Cianni","year":"2018","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Burtoloso, A.C.B., de Albuquerque, S., Furber, M., Gomes, J.C., Gon\u00e7alez, C., Kenny, P.W., Leit\u00e3o, A., Montanari, C.A., Quilles, J.C., and Ribeiro, J.F.R. (2017). Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005343"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"115083","DOI":"10.1016\/j.bmc.2019.115083","article-title":"Synthesis and structure-activity relationship of nitrile-based cruzain inhibitors incorporating a trifluoroethylamine-based P2 amide replacement","volume":"27","author":"Gomes","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1128\/AAC.01855-13","article-title":"Reversible Cysteine Protease Inhibitors Show Promise for a Chagas Disease Cure","volume":"58","author":"Ndao","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.bmcl.2010.10.015","article-title":"Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease","volume":"20","author":"Beaulieu","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1016\/j.bmcl.2017.10.002","article-title":"A comparative study of warheads for design of cysteine protease inhibitors","volume":"27","author":"Silva","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1002\/anie.200705858","article-title":"Azadipeptide Nitriles: Highly Potent and Proteolytically Stable Inhibitors of Papain-Like Cysteine Proteases","volume":"47","author":"Frizler","year":"2008","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1021\/acs.jcim.9b01138","article-title":"Assessment of the Cruzain Cysteine Protease Reversible and Irreversible Covalent Inhibition Mechanism","volume":"60","author":"Silva","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/1573406412666160701022230","article-title":"Synthesis, Biological Evaluation and Molecular Docking of New Benzenesulfonylhydrazone as Potential anti-Trypanosoma cruzi Agents","volume":"13","author":"Oliveira","year":"2017","journal-title":"Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11030-020-10156-5","article-title":"Synthesis and biological evaluation in vitro and in silico of N-propionyl-N\u2032-benzeneacylhydrazone derivatives as cruzain inhibitors of Trypanosoma cruzi","volume":"26","author":"Rivera","year":"2022","journal-title":"Mol. Divers."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"116213","DOI":"10.1016\/j.bmc.2021.116213","article-title":"Computer-aided design of 1,4-naphthoquinone-based inhibitors targeting cruzain and rhodesain cysteine proteases","volume":"41","author":"Silva","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1073\/pnas.0509010103","article-title":"Crystal structure, catalytic mechanism, and mitogenic properties of Trypanosoma cruzi proline racemase","volume":"103","author":"Buschiazzo","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Berneman, A., Montout, L., Goyard, S., Chamond, N., Cosson, A., d\u2019Archivio, S., Gouault, N., Uriac, P., Blondel, A., and Minoprio, P. (2013). Combined Approaches for Drug Design Points the Way to Novel Proline Racemase Inhibitor Candidates to Fight Chagas\u2019 Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060955"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2958.2005.04808.x","article-title":"Trypanosoma cruzi proline racemases are involved in parasite differentiation and infectivity: Trypanosoma cruzi proline racemases","volume":"58","author":"Chamond","year":"2005","journal-title":"Mol. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Amaral, P.d.A., Autheman, D., de Melo, G.D., Gouault, N., Cupif, J.-F., Goyard, S., Dutra, P., Coatnoan, N., Cosson, A., and Monet, D. (2018). Designed mono- and di-covalent inhibitors trap modeled functional motions for Trypanosoma cruzi proline racemase in crystallography. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006853"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jgar.2021.10.030","article-title":"Prodrugs as new therapies against Chagas disease: In vivo synergy between Trypanosoma cruzi proline racemase inhibitors and benznidazole","volume":"28","author":"Coatnoan","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Beig, M., Oellien, F., Garoff, L., Noack, S., Krauth-Siegel, R.L., and Selzer, P.M. (2015). Trypanothione Reductase: A Target Protein for a Combined In Vitro and In Silico Screening Approach. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003773"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Battista, T., Colotti, G., Ilari, A., and Fiorillo, A. (2020). Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases. Molecules, 25.","DOI":"10.3390\/molecules25081924"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1021\/acs.jmedchem.9b00294","article-title":"Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and Trypanosoma cruzi Cruzain","volume":"62","author":"Boudreau","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_74","unstructured":"Da Silva, E.B., Sharma, V., Hernandez-Alvarez, L., Tang, A.H., Stoye, A., O\u2019Donoghue, A.J., Gerwick, W.H., Payne, R.J., McKerrow, J.H., and Podust, L. (2023, March 17). Intramolecular Interactions Enhance the Potency of Gallinamide a Analogs against Trypanosoma cruzi. Available online: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.22.473926."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/13543776.2013.743992","article-title":"Falcipain inhibitors as potential therapeutics for resistant strains of malaria: A patent review","volume":"23","author":"Mane","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/cmdc.201200274","article-title":"Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipain-2 Inhibitors","volume":"7","author":"Ettari","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1021\/acs.jmedchem.9b00504","article-title":"Falcipain Inhibitors Based on the Natural Product Gallinamide A Are Potent in Vitro and in Vivo Antimalarials","volume":"62","author":"Stoye","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.1021\/acs.jmedchem.8b01161","article-title":"Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome","volume":"61","author":"Xie","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e2107213118","DOI":"10.1073\/pnas.2107213118","article-title":"Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome","volume":"118","author":"Xie","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/PL00000884","article-title":"Strategies for the inhibition of serine proteases","volume":"58","author":"Walker","year":"2001","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Stokes, B.H., Yoo, E., Murithi, J.M., Luth, M.R., Afanasyev, P., da Fonseca, P.C.A., Winzeler, E.A., Ng, C.L., Bogyo, M., and Fidock, D.A. (2019). Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. PLOS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007722"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7465","DOI":"10.1021\/jm500747h","article-title":"Discovery of Covalent Inhibitors of Glyceraldehyde-3-phosphate Dehydrogenase, A Target for the Treatment of Malaria","volume":"57","author":"Bruno","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.bmc.2016.04.033","article-title":"Selectivity of 3-bromo-isoxazoline inhibitors between human and Plasmodium falciparum glyceraldehyde-3-phosphate dehydrogenases","volume":"24","author":"Bruno","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8514","DOI":"10.1021\/bi300863a","article-title":"Heme Binding Properties of Glyceraldehyde-3-phosphate Dehydrogenase","volume":"51","author":"Hannibal","year":"2012","journal-title":"Biochemistry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1021\/acsmedchemlett.1c00354","article-title":"Development of Potent 3-Br-isoxazoline-Based Antimalarial and Antileishmanial Compounds","volume":"12","author":"Galbiati","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/cmdc.201500496","article-title":"Inspired by Nature: The 3-Halo-4,5-dihydroisoxazole Moiety as a Novel Molecular Warhead for the Design of Covalent Inhibitors","volume":"11","author":"Pinto","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molbiopara.2004.10.007","article-title":"A Plasmodium falciparum FK506-binding protein (FKBP) with peptidyl\u2013prolyl cis\u2013trans isomerase and chaperone activities","volume":"139","author":"Monaghan","year":"2005","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1107\/S1399004715006239","article-title":"Two crystal structures of the FK506-binding domain of Plasmodium falciparum FKBP35 in complex with rapamycin at high resolution","volume":"71","author":"Bianchin","year":"2015","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.bmcl.2015.05.079","article-title":"Computational insights into the suicide inhibition of Plasmodium falciparum Fk506-binding protein 35","volume":"25","author":"MacDonald","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1021\/acsmedchemlett.0c00272","article-title":"Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35","volume":"11","author":"Atack","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1021\/jm501439w","article-title":"Synthesis of Gallinamide A Analogues as Potent Falcipain Inhibitors and Antimalarials","volume":"57","author":"Conroy","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_93","unstructured":"(2023, March 17). Trypanosomiasis, Human African (Sleeping Sickness). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/trypanosomiasis-human-african-(sleeping-sickness)."},{"key":"ref_94","unstructured":"(2023, March 17). Chagas Disease (American Trypanosomiasis). Available online: https:\/\/www.who.int\/health-topics\/chagas-disease."},{"key":"ref_95","unstructured":"(2023, March 17). Fact Sheet about Malaria. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1087057116671509","article-title":"A Perspective on the Kinetics of Covalent and Irreversible Inhibition","volume":"22","author":"Strelow","year":"2017","journal-title":"SLAS Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0707354","article-title":"Human African trypanosomiasis: Pharmacological re-engagement with a neglected disease: Drugs for human African trypanosomiasis","volume":"152","author":"Barrett","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1098\/rstb.2008.0151","article-title":"Inflammation and oxidative stress in vertebrate host\u2013parasite systems","volume":"364","author":"Sorci","year":"2009","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.molbiopara.2015.11.003","article-title":"Thiol redox biology of trypanosomatids and potential targets for chemotherapy","volume":"206","author":"Leroux","year":"2016","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/anie.201810470","article-title":"Inhibitor-Induced Dimerization of an Essential Oxidoreductase from African Trypanosomes","volume":"58","author":"Wagner","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature16936","article-title":"Structure- and function-based design of Plasmodium-selective proteasome inhibitors","volume":"530","author":"Li","year":"2016","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e202115157","DOI":"10.1002\/ange.202115157","article-title":"Reversible Covalent Headpiece Enables Interconversion between Double- and Single-Stranded DNA-Encoded Chemical Libraries","volume":"134","author":"Zhao","year":"2022","journal-title":"Angew. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1021\/acsmedchemlett.2c00127","article-title":"Triazine-Based Covalent DNA-Encoded Libraries for Discovery of Covalent Inhibitors of Target Proteins","volume":"13","author":"Li","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.drudis.2020.03.016","article-title":"Covalent fragment libraries in drug discovery","volume":"25","author":"Keeley","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1039\/D3CB00057E","article-title":"Predicting small molecule binding pockets on diacylglycerol kinases using chemoproteomics and AlphaFold","volume":"4","author":"Mendez","year":"2023","journal-title":"RSC Chem. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4155\/fmc-2020-0118","article-title":"Covalent inhibitors: Back on track?","volume":"12","author":"Gehringer","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_107","unstructured":"DNDi Am\u00e9rica Latina (2023, May 02). Doen\u00e7as\u2014Iniciativa Medicamentos para Doen\u00e7as Negligenciadas. Available online: https:\/\/dndial.org\/doencas\/."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/1028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:15:12Z","timestamp":1760127312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/1028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":107,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ph16071028"],"URL":"https:\/\/doi.org\/10.3390\/ph16071028","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}